The efficacy and safety of toremifene-ifosfamide as a first-line chemo
therapy in non-small cell lung cancer were assessed. Sixteen patients
were treated with oral toremifene (420 mg on days 1-4 and 240 mg on da
y 5) followed by ifosfamide infusion 5 g/m(2) on day 5 every 3 weeks 1
-6 times. Toremifene at the doses used did not enhance the effect or t
oxicity of ifosfamide in previously untreated non-small cell lung canc
er patients. Copyright (C) 1996 Elsevier Science Ireland Ltd.